Oral Contraceptives in the Metabolic Syndrome.

Trial Profile

Oral Contraceptives in the Metabolic Syndrome.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Ethinylestradiol/norgestimate (Primary)
  • Indications Pregnancy
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Mar 2017 Planned End Date changed from 1 Jun 2014 to 1 Dec 2017.
    • 24 May 2013 Planned End Date changed from 1 Jun 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top